NVCR — NovoCure Ltd

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1645113 · Jersey
Last close
$14.84
Market Cap
$1.73B
52W High
$21.45
52W Low
$13.43
ADV30
1,930,287
Next earnings
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 183,584,000 142,478,000 -10,562,000 -15,658,000 795,191,000 93,701,000 457,099,000
Mar 2026 174,055,000 135,126,000 -67,420,000 -71,138,000 787,926,000 87,527,000 457,209,000
Dec 2025 174,350,000 132,193,000 -40,393,000 -24,499,000 804,326,000 93,548,000 463,860,000
Sep 2025 167,204,000 122,475,000 -36,021,000 -37,270,000 1,361,194,000 342,119,000 1,019,861,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-26,883,000
Investing CF
$451,495,000
Financing CF
$-456,756,000
CapEx
$-21,189,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.53
As of
2026-07-26

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,361,495,000
Inventory
$43,458,000
Receivables
$146,404,000
ST Investments
$344,477,000
EBIT TTM
$-148,768,000
Pretax Income TTM
$-175,213,000
Interest Exp TTM
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$699,193,024
EBITDA
$-136,392,992
Free Cash Flow
$22,763,750
Enterprise Value
$1,566,331,136
Total Cash
$440,559,008
Total Debt
$233,420,000
Shares Out
116,445,840
Trailing EPS
$-1.30
Book Value
$2.90
ROE
-43.2%
ROA
-9.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 655,353,000 -153,800,000 -136,227,000 804,326,000 463,860,000 -49,031,000
Dec 2024 605,220,000 -170,496,000 -168,627,000 1,240,784,000 880,605,000 -26,369,000
Dec 2023 509,338,000 -232,870,000 -207,043,000 1,146,129,000 783,633,000 -73,336,000
Dec 2022 537,840,000 -89,523,000 -92,534,000 1,191,648,000 750,478,000 30,788,000

TTM Snapshot

Revenues TTM
$547,020,000
NetIncome TTM
$-119,755,000
OpCashFlow TTM
$0
Assets (Latest)
$1,240,784,000
Forward EPS
$-0.92

Peers — same industry

TickerNameMarket CapLastDaily %
BFLY Butterfly Network, Inc. $1.74B $7.11
ENOV Enovis CORP $1.68B $29.15
ATRC AtriCure, Inc. $1.92B $37.76
BLFS BIOLIFE SOLUTIONS INC $1.53B $31.28
UFPT UFP TECHNOLOGIES INC $1.97B $254.78

News headlines (Yahoo Finance, 1h cache)

NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?
2026-07-27 16:00 · Yahoo
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade
2026-07-27 13:55 · Yahoo
Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects
2026-07-27 13:15 · Yahoo
NovoCure (NVCR) Lifts 2026 Guidance After Record Quarter While Fair Value Debate Builds
2026-07-25 07:11 · Yahoo
NovoCure Limited Q2 2026 Earnings Call Summary
2026-07-24 12:30 · Yahoo
Why Did CSX, UNP, NVCR Stocks Surge To 52-Week Highs Today?
2026-07-24 03:45 · Yahoo
Novocure (NVCR) Hits New High on Optimistic Outlook, FDA Approval Hopes
2026-07-24 00:43 · Yahoo
Novocure Flashes A Bullish Signal As It Breaks Out. Have Shares 'Turned A Corner?'
2026-07-23 20:16 · Yahoo
NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally?
2026-07-23 20:09 · Yahoo
NovoCure Ltd (NVCR) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...
2026-07-23 19:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.